Can Semaglutide offer hope for patients with obesity-related heart failure?

Autor: Olatunji G; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria. Electronic address: gbolahanolatunji153@gmail.com., Aderinto N; Department of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, Ogbomoso, Nigeria. Electronic address: nicholasoluwaseyi6@gmail.com., Kokori E; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria., Ogieuhi IJ; Siberian State Medical University, Tomsk, Russia., Abraham IC; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria., Olanisa O; Trinity Health Grand Rapids, Michigan, USA., Nebuwa C; Nuvance Health, Vassar Brothers Medical Center, Poughkeepsie, New York, USA., Awoyinfa M; College of Medicine, University of Lagos, Nigeria., Ajimotokan O; Babcock University Teaching Hospital, Ogun, Nigeria., Ajayi JO; Kharkiv National Medical University, Ukraine., Rao NN; Johns Hopkins Bloomberg School of Public Health, USA., Temidayo AO; Faculty of Pharmacy, University of Lagos, Nigeria., Napoleon T; Federal Medical Centre, Abeokuta, Nigeria., Samuel O; Lagos State Health Service Commission, Nigeria., Ezeano C; University of North Texas, Health Science Center, Fort Worth, Texas, USA.
Jazyk: angličtina
Zdroj: Current problems in cardiology [Curr Probl Cardiol] 2024 Sep; Vol. 49 (9), pp. 102697. Date of Electronic Publication: 2024 Jun 11.
DOI: 10.1016/j.cpcardiol.2024.102697
Abstrakt: Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge with limited treatment options. This review explores the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for HFpEF treatment. Studies suggest promising benefits, including symptom improvement, weight management, and the potential for enhanced exercise capacity. However, the evidence for semaglutide's impact on exercise capacity and heart function remains inconclusive, and its anti-inflammatory effects require further investigation. The safety profile appears favorable, with gastrointestinal side effects being the most common adverse events. It is crucial to emphasize that additional research with longer follow-up, head-to-head comparisons, and exploration of optimal dosage and mechanisms of action are necessary to solidify semaglutide's role in HFpEF treatment. Semaglutide is promising to improve symptoms, promote weight loss, and potentially influence underlying HFpEF mechanisms. Future research can refine treatment strategies and unlock the full potential of semaglutide for this patient population.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: